{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-344878","form_type":"8-K","ticker":"MAZE","cik":"0001842295","company_name":"Maze Therapeutics, Inc.","filed_at":"2026-08-11T20:45:16+00:00","discovered_at":"2026-08-11T20:46:01.874760+00:00","generated_at":"2026-08-11T20:46:12.718489+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Maze Therapeutics Q2 2026: cash $494.9M, net loss $44.7M; pipeline milestones on track","bullets":["Cash, equivalents and marketable securities $494.9M at 6/30/26 vs $360.0M at 12/31/25; runway into 2029.","Q2 2026 net loss $44.7M ($0.76/share) vs $33.7M ($0.77/share) in Q2 2025; H1 loss $68.9M ($1.22/share).","R&D expenses Q2 $34.9M (vs $28.1M); G&A $13.1M (vs $8.4M); both up on clinical progress and personnel costs.","Recognized $20M H1 2026 license revenue from Shionogi milestone for MZE001 (Pompe disease).","MZE829 HORIZON updated data late 2026/early 2027 (3 cohorts); pivotal trial H1 2027. MZE782 PKU topline 2027; CKD trial H1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-344878","json":"https://secwatch.observer/filing/0001193125-26-344878.json","markdown":"https://secwatch.observer/filing/0001193125-26-344878.md","text":"https://secwatch.observer/filing/0001193125-26-344878.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842295/000119312526344878/0001193125-26-344878-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842295/000119312526344878/maze-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T20:46:12.718489+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}